In its report to the FDA panel, AstraZeneca stated, "The failure to reach statistical significance for survival in the overall population was completely unexpected," noting that Iressa has been successful at shrinking tumors in people of Asian descent and nonsmokers. AstraZeneca said a decision on whether to pull Iressa from the market should not be made until an analysis of data from the clinical trial is complete, likely in May or June ( AP/Contra Costa Times, 3/7). Dr. Otis W. Brawley, a panel member and oncologist at Emory University, said, "The development of this drug has been mishandled," adding, "It's been mishandled by AstraZeneca. It's been mishandled by this committee. We still haven't figured out how it should be used." Dr. Peter Lurie, deputy director for health research for Public Citizen, said, "If this drug is not taken off the market on these grounds, it will make an absolute mockery" of the accelerated approval program ( New York Times, 3/5).